Germany's U3 Pharma has raised $34 million in a new round led by Life Sciences Partners. U3 has been developing antibody-based targeted cancer therapeutics. Its lead products are nearing the clinic. U3 Pharma also announced that Dr. Karsten Henco has been appointed as CEO.
- here's the release for more information